Status
Conditions
Treatments
About
RADAR-Septic Shock is a population-based observational study in Catalonia (Spain) that will identify all hospital discharges with septic shock between 2018 and 2023 using an audited population-based registry. The project will quantify incidence, describe patient characteristics and resource use, and compare risk-adjusted in-hospital mortality across hospitals to support quality improvement. Cases are defined by ICD-10 codes for septic shock (R65.21) and post-procedural septic shock (T81.12XA). In preliminary cohort counts, >31,000 episodes were identified across 2018-2023; in 2023 the incidence was ~78 per 100,000 inhabitants with an overall in-hospital mortality of ~33%, higher in hospital-acquired than community-acquired episodes
Full description
Septic shock is the most severe manifestation of sepsis and remains a leading cause of death and healthcare utilisation. Outcomes vary by patient mix (age, comorbidities), acquisition setting, infection source, and hospital performance, underscoring the need for robust, population-level surveillance to guide policy and care pathways. RADAR-Septic Shock leverages routinely collected administrative data to provide standardised measures of incidence, resource use, and outcomes across an entire regional health system.
The study aims to quantify the population incidence of septic shock and describe patient demographics, comorbidity burden, infection sources, organ failures, and use of life-support therapies; 2) estimate in-hospital and short-term mortality and length of stay; and 3) benchmark hospitals using risk-adjusted observed-to-expected (O/E) mortality to identify variation and inform improvement strategies.
It is a population-based cohort using the Catalan Minimum Basic Data Set for Acute Care Hospitals (CMBD-HA), an audited, mandatory discharge registry covering all acute-care hospitals in the public system. The analytic period spans January 2018-December 2023.
It will include all hospital discharges containing a primary or secondary diagnosis code for septic shock (ICD-10-CM R65.21) or post-procedural septic shock (T81.12XA). This definition prioritises specificity and uniformity across centres. Episodes will be stratified by acquisition setting (community- vs hospital-acquired).
Extracted variables include: demographics (age, sex); comorbidities and morbidity burden (Adjusted Morbidity Groups [GMA] index); infection source; organ failures; advanced life-support interventions (mechanical ventilation, renal replacement therapy, ECMO); ICU admission; length of stay; and mortality.
Primary outcome: in-hospital mortality. Secondary outcomes: 30-day mortality (where available), ICU admission, length of stay, and use of life-support therapies. Preliminary registry summaries show >31,000 episodes across 2018-2023 and, for 2023, an incidence of ~78 per 100,000 with in-hospital mortality ~33% overall (higher in hospital-acquired episodes). These figures motivate the benchmarking component.
Descriptive statistics will summarise case mix and care processes, including incidence rates per 100,000 inhabitants. Multivariable logistic regression will estimate individual mortality risk; model performance will be assessed (e.g., AUROC) and used to generate expected mortality for each hospital. Comparative performance will be reported via O/E mortality ratios with confidence intervals. Length of stay will be modelled after appropriate transformation. Sensitivity analyses will explore the impact of acquisition setting, infection source, organ failures, and comorbidity burden.
Based on audited counts, the registry includes 31,480 septic shock episodes over 2018-2023 (6,182 in 2023), ensuring sufficient precision for risk modelling and hospital-level benchmarking across the regional network.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
31,480 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal